Carter's (CRI) Earnings Analysis
Carter's (CRI) next reports earnings on 2026-07-24, consensus EPS 0.06121 USD. Last quarter (2026-02-27) it beat with EPS 1.9 USD vs 1.7 USD est (+11.8%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E 15.10.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CRI next report earnings?
| Next earnings date | 2026-07-24 |
|---|---|
| Consensus EPS estimate | 0.06121 USD |
| Revenue estimate | 0.61B |
CRI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-27 | 1.9 USD | 1.7 USD | +11.8% | Beat |
| 2025-10-27 | 0.74 USD | 0.78 USD | -5.1% | Miss |
| 2025-07-25 | 0.17 USD | 0.43 USD | -60.5% | Miss |
| 2025-04-25 | 0.66 USD | 0.53 USD | +24.5% | Beat |
| 2024-10-25 | 1.62 USD | 1.4 USD | +15.7% | Beat |
| 2024-07-26 | 0.76 USD | 0.49 USD | +55.1% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
CRI valuation and analyst view
| Trailing P/E | 15.10 |
|---|---|
| Trailing EPS | 2.556 USD |
| Price / book | 1.46 |
| Dividend yield | 2.61% |
| Market cap | 1.43B |
| Analyst consensus | Buy (12 buy / 9 hold / 3 sell) |
| Avg price target | 38.67 USD |
Related research pages
Frequently asked questions
When is Carter's (CRI)'s next earnings date?
Carter's is next scheduled to report on 2026-07-24, with a consensus EPS estimate of 0.06121 USD and revenue estimate of 0.61B.
Did CRI beat earnings last quarter?
In its 2026-02-27 report, CRI posted EPS of 1.9 USD versus a 1.7 USD estimate — a beat of 11.8%.
What is CRI's earnings track record?
Over the last 6 reported quarters with consensus data, CRI beat estimates 4 times (67%).
What is CRI's current P/E ratio and EPS?
CRI trades at a trailing P/E of 15.10 on trailing EPS of 2.555968178502297 USD.
What do analysts rate CRI?
Analyst consensus is "Buy" across 24 ratings (0 strong buy, 12 buy, 9 hold, 3 sell, 0 strong sell). Average 12-month price target: 38.67 USD.